GEN April 2022 Page 36

"With MatchMaker at hand, we were able to replace our reliance on conventional molecular docking in our fl agship proteome screening platform Ligand Express," the blog post detailed. "MatchMaker also plays a critical role in our newly launched Ligand Design technology for multi-objective drug design. Taken together, Ligand Design and Ligand Express, our fi rst-generation off-target profi ling platform, offer a unique end-to-end AI-augmented drug discovery platform to design ad-vanced lead-like molecules while minimizing off-target effects." Turning speci c details into generalizable rules Molly Gibson, PhD, is the co-founder of Generate Bio-medicines, a biotech company that uses a machine learning platform called Generative Biology to expedite the discovery of protein-based drugs. The platform, which leverages statistics to uncover patterns linking amino acid sequence, structure, and function, is designed to expand the available search space for novel biomedicines.